This content is from: Premium Inside the Trade: Addicted to Allergan The Allergan-Valeant takeover saga may be long over, but there’s still some life left in the trade. August 19, 2015
This content is from: Portfolio Proxy Advisors Back Allergan Over Appaloosa in Latest Scuffle Appaloosa wants to replace Allergan’s chairman and install an independent pharmaceutical executive in that role. ISS and Glass Lewis recommend that shareholders vote against it. By Alicia McElhaney April 15, 2019
This content is from: Portfolio The Morning Brief: Pershing Square’s Ackman Wins Court Battle with Allergan By Stephen Taub November 05, 2014
This content is from: Premium Inside the Trade: What Bill Ackman Sees in Valeant and Allergan The Pershing Square activist has avoided investing in drugmakers before, but he and Valeant CEO Michael Pearson understand each other By Michael Peltz August 22, 2014
This content is from: Portfolio Allergan-Pfizer Merger Gives Pharma a Growth Injection The $160 billion all-stock deal is the largest-ever tax inversion and pharmaceutical sector merger. By Anne Szustek December 16, 2015
This content is from: Portfolio The Morning Brief: Pershing Square Sues Allergan in Takeover Bid By Stephen Taub June 16, 2014
